

# **Supplemental Material**

**Table S1. Characteristics of the study population (at visit 4) by the presence of carotid plaques at visit 4.**

<b>Patients` characteristics at V4</b>	<b>No plaque</b>	<b>Plaque at V4</b>	<b>p-value</b>
N. total =997	794	203	
Age (yr)	58.7 ± 5.8	61.4 ± 5.2	<0.001
Male sex	387 (48.7%)	122 (60.1%)	0.004
BMI (Kg/m <sup>2</sup> )	26.9 ± 4.8	27.4 ± 4.8	0.16
Waist circumference (cm)	92.6 ± 13.3	95.7 ± 13.6	0.003
Smoking	99 (12.5%)	29 (14.4%)	0.46
SBP (mmHg)	128.2 ± 15.5	134.4 ± 16.9	<0.001
DBP (mmHg)	74.3 ± 8.8	74.4 ± 9.0	0.87
Heart rate (bpm)	63.5 ± 8.9	62.7 ± 10.5	0.28
Diabetes	57 (7.3%)	21 (10.7%)	0.27
Glucose (g/L)	0.9 ± 0.2	1.0 ± 0.2	<0.001
Hypertension history	225 (28.4%)	76 (37.8%)	0.010
Total cholesterol (g/L)	2.2 ± 0.4	2.2 ± 0.4	0.46
HDL cholesterol (g/L)	0.6 ± 0.1	0.6 ± 0.1	0.59
LDL cholesterol (g/L)	1.4 ± 0.3	1.4 ± 0.4	0.11
Triglycerides (g/L)	1.1 ± 0.8	1.2 ± 0.6	0.033
Lipid lowering therapy	181 (22.8%)	71 (35.0%)	<0.001
eGFR (ml/min)	88.3 ± 12.0	89.1 ± 12.9	0.41
Carotid stenosis 20-50%	0 (0.0%)	15 (100.0%)	<0.001
cIMT (µm)	691 ± 138	722 ± 132	0.005
PWV (m/s)	9.0 ± 1.7	9.8 ± 2.1	<0.001
PCSK9 (NPX)	2.9 ± 0.4	3.0 ± 0.4	<0.001
LDL receptor (NPX)	5.5 ± 0.6	5.6 ± 0.5	0.016

BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate calculated by the CKD-EPI formula; LDL, low-density lipoprotein; cIMT, carotid intima-media thickness; PWV, pulse-wave velocity; PCSK9, proprotein convertase subtilisin/kexin type 9; NPX, Olink® log2 standardized units.

**Table S2. Factors associated with carotid artery plaque at visit 4.**

<b>Variable</b>	<b>OR (95%CI)</b>	<b>p-value</b>
<b>“Best” clinical model</b>		
Age (per 5 yr)	1.48 (1.26-1.73)	<0.001
SBP (per 10 mmHg)	1.18 (1.07-1.30)	0.001
Lipid-lowering therapy	1.39 (0.98-1.97)	0.062
<b>PCSK9 plus LDLr on top of the “best” clinical model</b>		
PCSK9 (NPX)	1.66 (1.01-2.72)	0.045
LDLr (NPX)	1.12 (0.82-1.53)	0.48
<b>PCSK9/LDLr ratio on top of the “best” clinical model</b>		
PCSK9/LDLr (ratio)	1.13 (0.89-1.43)	0.33

N =997; N. Plaque =203.

LDLc, low-density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9; LDLr, LDL receptor; NPX, Olink® log2 standardized units.

**Table S3. Plaque at visit 4 in the “children”.**

<b>Children at V1</b>	<b>No plaque</b>	<b>Plaque at V4</b>
N. total =647	641 (99.1%)	6 (0.9%)

**Table S4. Association of PCSK9 and LDLr (visit 1 and visit 4) with IMT and PWV (at visit 4).**

<b>Visit 1 (PCSK9 and LDLr)</b>		
<b>IMT above the 90<sup>th</sup> percentile</b>	<b>OR (95%CI)</b>	<b>p-value</b>
PCSK9 (NPX)	1.03 (0.67-1.61)	0.87
LDLr (NPX)	1.11 (0.84-1.47)	0.45
<b>IMT (mm) continuous</b>	<b>Coef. (95%CI)</b>	<b>p-value</b>
PCSK9 (NPX)	16.1 (-10.7 to +42.8)	0.24
LDLr (NPX)	11.8 (-5.2 to +28.7)	0.18
<b>PWV above the 90<sup>th</sup> percentile</b>	<b>OR (95%CI)</b>	<b>p-value</b>
PCSK9 (NPX)	1.01 (0.46-2.20)	0.98
LDLr (NPX)	1.23 (0.75-2.01)	0.41
<b>PWV (m/s) continuous</b>	<b>Coef. (95%CI)</b>	<b>p-value</b>
PCSK9 (NPX)	-0.1 (-0.4 to +0.3)	0.60
LDLr (NPX)	0.4 (+0.1 to +0.6)	0.002
<b>Visit 4 (PCSK9 and LDLr)</b>		
<b>IMT above the 90<sup>th</sup> percentile</b>	<b>OR (95%CI)</b>	<b>p-value</b>
PCSK9 (NPX)	0.87 (0.58-1.30)	0.51
LDLr (NPX)	1.32 (1.00-1.73)	0.042
<b>IMT (mm) continuous</b>	<b>Coef. (95%CI)</b>	<b>p-value</b>
PCSK9 (NPX)	-2.9 (-27.4 to +21.5)	0.81
LDLr (NPX)	20.9 (+4.5 to +37.2)	0.012
<b>PWV above the 90<sup>th</sup> percentile</b>	<b>OR (95%CI)</b>	<b>p-value</b>
PCSK9 (NPX)	1.09 (0.55-2.18)	0.79
LDLr (NPX)	1.17 (0.74-1.84)	0.51
<b>PWV (m/s) continuous</b>	<b>Coef. (95%CI)</b>	<b>p-value</b>
PCSK9 (NPX)	0.1 (-0.3 to +0.3)	0.92
LDLr (NPX)	0.1 (-0.1 to +0.3)	0.27

Model adjusted on age, sex, smoking and LDLc.

**Table S5. Association between presence of plaques and PCSK9 polymorphisms (n=949).**

<b>id</b>	<b>Allele 1</b>	<b>Allele 2</b>	<b>freqA2</b>	<b>beta</b>	<b>sd</b>	<b>p</b>	<b>BH</b>
rs2479394	G	A	0.702	0.124	0.132	0.348	0.566
rs11588151	G	A	0.778	0.151	0.151	0.318	0.566
rs11206510	C	T	0.795	0.256	0.157	0.103	0.269
rs17192725	A	G	0.900	0.013	0.200	0.950	0.950
rs2182833	G	A	0.800	-0.141	0.150	0.348	0.566
rs2479409	G	A	0.655	-0.281	0.125	0.025	0.130
rs11591147	T	G	0.985	0.120	0.513	0.814	0.847
rs11583680	T	C	0.856	0.409	0.190	0.032	0.137
rs499718	T	C	0.815	0.101	0.159	0.524	0.632
rs28385708	T	C	0.932	0.163	0.245	0.507	0.632
rs41294821	T	C	0.990	-0.559	0.545	0.305	0.566
rs7552841	T	C	0.600	0.037	0.124	0.768	0.832
rs58255540	G	A	0.948	-0.209	0.255	0.412	0.630
rs634272	T	C	0.741	0.412	0.147	0.005	0.032
rs11808052	T	C	0.948	-0.134	0.259	0.604	0.683
rs540796	A	G	0.838	0.578	0.188	0.002	0.024
rs562556	G	A	0.838	0.584	0.188	0.002	0.024
rs114162366	A	G	0.981	-0.301	0.403	0.455	0.632
rs631220	A	G	0.838	0.562	0.187	0.003	0.024
rs505151	G	A	0.968	0.248	0.377	0.510	0.632
rs41294827	T	G	0.973	-0.653	0.333	0.050	0.143
rs77011887	T	C	0.979	-0.443	0.386	0.251	0.544
rs77868073	C	T	0.974	-0.673	0.334	0.044	0.142
rs487230	A	G	0.784	0.327	0.159	0.039	0.142
rs114527615	A	G	0.980	0.289	0.466	0.535	0.632
rs17111584	C	T	0.968	-0.487	0.309	0.114	0.271

**Table S6. Crude odd ratios for association between plaques at V4 and genotype at rs562556.**

	Plaques (n=184)	No plaques (n=718)	OR (95%CI) (risk per A allele)	P trend
Rs562556				
GG	0	24		
GA	41	201	1.67 (1.17-2.38)	P = 0.004
AA	143	493		

**Table S7. Association between *PCSK9* polymorphisms and circulating LDL at visit 4 (n=895).**

<b>id</b>	<b>Allele 1</b>	<b>Allele 2</b>	<b>freqA2</b>	<b>beta</b>	<b>sd</b>	<b>p</b>	<b>BH</b>
rs2479394	G	A	0.703	-0.019	0.017	0.273	0.671
rs11588151	G	A	0.777	-0.010	0.019	0.617	0.895
rs11206510	C	T	0.794	-0.017	0.020	0.382	0.671
rs17192725	A	G	0.899	-0.013	0.026	0.619	0.895
rs2182833	G	A	0.800	-0.016	0.020	0.416	0.675
rs2479409	G	A	0.654	-0.006	0.017	0.703	0.918
rs11591147	T	G	0.985	0.080	0.065	0.218	0.671
rs11583680	T	C	0.856	-0.025	0.023	0.269	0.671
rs499718	T	C	0.815	-0.007	0.020	0.747	0.925
rs28385708	T	C	0.931	-0.027	0.031	0.387	0.671
rs41294821	T	C	0.990	-0.004	0.079	0.964	0.964
rs7552841	T	C	0.601	-0.018	0.016	0.269	0.671
rs58255540	G	A	0.948	0.032	0.035	0.358	0.671
rs634272	T	C	0.741	-0.007	0.018	0.706	0.918
rs11808052	T	C	0.948	0.033	0.035	0.343	0.671
rs540796	A	G	0.837	0.053	0.021	0.012	0.088
rs562556	G	A	0.837	0.052	0.021	0.014	0.088
rs114162366	A	G	0.980	-0.005	0.057	0.929	0.964
rs631220	A	G	0.838	0.053	0.021	0.011	0.088
rs505151	G	A	0.968	-0.006	0.045	0.888	0.964
rs41294827	T	G	0.973	0.069	0.049	0.161	0.671
rs77011887	T	C	0.979	-0.005	0.055	0.930	0.964
rs77868073	C	T	0.974	0.063	0.049	0.202	0.671
rs487230	A	G	0.783	0.048	0.019	0.013	0.088
rs114527615	A	G	0.980	-0.013	0.056	0.815	0.963
rs17111584	C	T	0.968	0.042	0.044	0.340	0.671



**Table S8. Association between *PCSK9* polymorphisms and circulating LDL at visit 1 (n=861).**

<b>id</b>	<b>Allele 1</b>	<b>Allele 2</b>	<b>freqA2</b>	<b>beta</b>	<b>sd</b>	<b>p</b>	<b>BH</b>
rs2479394	G	A	0.699	-0.011	0.018	0.534	0.816
rs11588151	G	A	0.776	0.050	0.020	0.015	0.077
rs11206510	C	T	0.793	0.033	0.021	0.113	0.327
rs17192725	A	G	0.899	-0.056	0.028	0.042	0.156
rs2182833	G	A	0.797	-0.025	0.021	0.248	0.538
rs2479409	G	A	0.653	-0.034	0.018	0.054	0.176
rs11591147	T	G	0.985	0.190	0.068	0.005	0.077
rs11583680	T	C	0.856	0.012	0.024	0.605	0.828
rs499718	T	C	0.814	-0.006	0.021	0.778	0.963
rs28385708	T	C	0.932	0.007	0.033	0.824	0.974
rs41294821	T	C	0.990	0.025	0.084	0.765	0.963
rs7552841	T	C	0.598	-0.024	0.017	0.155	0.393
rs58255540	G	A	0.948	0.029	0.037	0.439	0.761
rs634272	T	C	0.744	0.021	0.019	0.274	0.549
rs11808052	T	C	0.948	0.030	0.037	0.427	0.761
rs540796	A	G	0.838	0.057	0.022	0.011	0.077
rs562556	G	A	0.837	0.056	0.022	0.012	0.077
rs114162366	A	G	0.983	0.000	0.064	0.996	0.996
rs631220	A	G	0.839	0.059	0.022	0.009	0.077
rs505151	G	A	0.969	-0.112	0.048	0.021	0.090
rs41294827	T	G	0.974	0.007	0.053	0.897	0.996
rs77011887	T	C	0.979	-0.032	0.059	0.589	0.828
rs77868073	C	T	0.975	-0.001	0.054	0.984	0.996
rs487230	A	G	0.787	0.028	0.020	0.166	0.393
rs114527615	A	G	0.980	0.039	0.059	0.511	0.816
rs17111584	C	T	0.971	-0.004	0.050	0.935	0.996

**Table S9. Association between *PCSK9* polymorphisms and circulating *PCSK9* at visit 1 (n=894).**

<b>id</b>	<b>Allele 1</b>	<b>Allele 2</b>	<b>freqA2</b>	<b>beta</b>	<b>sd</b>	<b>p</b>	<b>BH</b>
rs2479394	G	A	0.702	-0.026	0.019	1.7E-01	2.9E-01
rs11588151	G	A	0.777	0.061	0.021	3.8E-03	9.5E-03
rs11206510	C	T	0.794	0.061	0.021	4.4E-03	9.5E-03
rs17192725	A	G	0.899	-0.038	0.028	1.8E-01	2.9E-01
rs2182833	G	A	0.800	-0.077	0.022	4.6E-04	1.3E-03
rs2479409	G	A	0.655	-0.048	0.018	7.7E-03	1.5E-02
rs11591147	T	G	0.985	0.326	0.070	3.4E-06	1.7E-05
rs11583680	T	C	0.855	0.120	0.024	8.8E-07	1.5E-05
rs499718	T	C	0.814	0.087	0.022	7.7E-05	2.5E-04
rs28385708	T	C	0.931	-0.023	0.034	5.1E-01	6.0E-01
rs41294821	T	C	0.990	0.053	0.086	5.4E-01	6.0E-01
rs7552841	T	C	0.601	-0.050	0.017	4.2E-03	9.5E-03
rs58255540	G	A	0.949	0.027	0.038	4.9E-01	6.0E-01
rs634272	T	C	0.740	0.089	0.019	4.0E-06	1.7E-05
rs11808052	T	C	0.949	0.031	0.038	4.2E-01	5.8E-01
rs540796	A	G	0.837	0.110	0.023	1.8E-06	1.5E-05
rs562556	G	A	0.837	0.110	0.023	1.7E-06	1.5E-05
rs114162366	A	G	0.980	-0.053	0.062	4.0E-01	5.7E-01
rs631220	A	G	0.837	0.108	0.023	2.5E-06	1.6E-05
rs505151	G	A	0.968	-0.063	0.049	2.1E-01	3.1E-01
rs41294827	T	G	0.973	0.023	0.054	6.7E-01	7.2E-01
rs77011887	T	C	0.979	-0.042	0.060	4.8E-01	6.0E-01
rs77868073	C	T	0.974	0.021	0.054	7.0E-01	7.3E-01
rs487230	A	G	0.783	0.083	0.021	7.3E-05	2.5E-04
rs114527615	A	G	0.980	0.120	0.061	5.1E-02	9.5E-02
rs17111584	C	T	0.968	0.002	0.049	9.7E-01	9.7E-01

**Table S10. Association between *PCSK9* polymorphisms and circulating *PCSK9* at visit 4 (n=897).**

<b>id</b>	<b>A1</b>	<b>A2</b>	<b>freqA2</b>	<b>beta</b>	<b>sd</b>	<b>p</b>	<b>BH</b>
rs2479394	G	A	0.702	-0.016	0.018	3.94E-01	5.12E-01
rs11588151	G	A	0.778	0.079	0.021	1.28E-04	3.70E-04
rs11206510	C	T	0.795	0.101	0.021	1.62E-06	1.05E-05
rs17192725	A	G	0.900	-0.031	0.028	2.68E-01	3.69E-01
rs2182833	G	A	0.800	-0.052	0.022	1.59E-02	2.96E-02
rs2479409	G	A	0.655	-0.065	0.018	2.63E-04	6.84E-04
rs11591147	T	G	0.985	0.429	0.068	5.46E-10	1.42E-08
rs11583680	T	C	0.856	0.143	0.024	3.75E-09	4.88E-08
rs499718	T	C	0.815	0.084	0.022	1.13E-04	3.67E-04
rs28385708	T	C	0.931	0.024	0.033	4.67E-01	5.78E-01
rs41294821	T	C	0.990	0.094	0.085	2.70E-01	3.69E-01
rs7552841	T	C	0.599	-0.053	0.017	2.23E-03	5.26E-03
rs58255540	G	A	0.949	0.091	0.038	1.78E-02	3.08E-02
rs634272	T	C	0.741	0.096	0.019	5.09E-07	4.41E-06
rs11808052	T	C	0.949	0.090	0.038	2.00E-02	3.25E-02
rs540796	A	G	0.838	0.103	0.023	6.34E-06	2.75E-05
rs562556	G	A	0.838	0.105	0.023	3.93E-06	2.04E-05
rs114162366	A	G	0.980	0.022	0.062	7.26E-01	7.55E-01
rs631220	A	G	0.839	0.102	0.023	7.68E-06	2.85E-05
rs505151	G	A	0.968	-0.139	0.049	4.51E-03	9.76E-03
rs41294827	T	G	0.973	0.031	0.053	5.52E-01	6.24E-01
rs77011887	T	C	0.979	0.015	0.059	7.98E-01	7.98E-01
rs77868073	C	T	0.974	0.035	0.053	5.16E-01	6.09E-01
rs487230	A	G	0.784	0.058	0.021	5.23E-03	1.05E-02
rs114527615	A	G	0.980	0.068	0.061	2.63E-01	3.69E-01
rs17111584	C	T	0.968	0.023	0.048	6.35E-01	6.88E-01

**Table S11. Partial correlation coefficients.**

<b>Variable</b>	<b>Partial correlation</b>	<b>P-value</b>
<b>PCSK9 levels at V1</b>		
Age at V1	-5.2%	0.12
Smoking at V1	-0.1%	0.77
LDLc at V1	15.0%	<0.001
LDLr at V1	37.6%	<0.001
rs562556	16.0%	<0.001
<b>PCSK9 levels at V4</b>		
Age at V4	-2.3%	0.49
SBP at V4	-1.5%	0.65
Statin at V4	30.0%	<0.001
LDLr at V4	36.5%	<0.001
rs562556	16.5%	<0.001

**Figure S1. Distribution of the Stanislas cohort population according to age.**



